Overview

Use of ACTIMMUNE in Patients With ADO2

Status:
Completed

Trial end date:
2019-11-12

Target enrollment:

Participant gender:

Summary

This study is an open label use of ACTIMMUNE for patients with Autosomal Dominant Osteopetrosis Type 2(ADO2). Effects of treatment will be evaluated after 14 weeks on ACTIMMUNE by bone resorption markers. This study will treat 12 patients with ADO2 recruited from Indiana University and Riley Hospital for Children at Indiana University Health.

Phase:

Phase 2

Details

Lead Sponsor:

Indiana University

Collaborator:

Horizon Pharma Ireland, Ltd., Dublin Ireland

Treatments:

Interferon-gamma